The threshold for disclosure of significant financial interests according to the 1998 FDA regulations is:

The threshold for disclosure of significant financial interests as per the 1998 FDA regulations is set at any equity interest exceeding $50,000. This means researchers involved in studies that require FDA oversight must disclose financial interests if they hold equity in a publicly traded company that surpasses this monetary amount. This regulation aims to identify potential conflicts of interest that could affect research integrity, ensuring transparency and accountability.

This threshold is crucial in protecting the integrity of the research process, as it allows for the evaluation of whether such financial interests might influence a researcher's work or the results of their studies. Researchers are expected to disclose these significant interests to promote ethical standards and maintain public trust in the research community.